{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T16:48:14Z","timestamp":1774630094166,"version":"3.50.1"},"reference-count":29,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2018,2,14]]},"abstract":"<jats:p>Tumour lysis syndrome (TLS) is a rare oncological emergency in solid tumours. Because it is associated with bad short-term prognosis, early recognition and treatment are mandatory. This case refers to a middle-aged woman who presented with stage IV colon cancer, with massive hepatic involvement. After three cycles of first-line FOLFOX (folinic acid, 5-fluorouracil and oxaliplatin), she developed acute kidney injury and hyperkalaemia that did not respond to standard measures. High suspicion of TLS prompted further corroborating investigations and early intensive care unit admission. With vigorous hydration and allopurinol, TLS completely resolved and the patient was discharged. Prophylaxis of subsequent TLS recurrence was complicated by biopsy-proven neutrophilic vasculitis secondary to allopurinol. Prevention of TLS with hydration and rasburicase was performed prior to each subsequent cycle of chemotherapy. This case report is intended to highlight risk factors for TLS in solid tumours and focus on treatment and secondary prophylaxis of TLS.<\/jats:p>","DOI":"10.1136\/bcr-2017-223474","type":"journal-article","created":{"date-parts":[[2018,3,15]],"date-time":"2018-03-15T09:38:30Z","timestamp":1521106710000},"page":"bcr-2017-223474","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Management of tumour lysis syndrome during first-line palliative chemotherapy for high-volume colorectal cancer"],"prefix":"10.1136","volume":"2018","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0841-194X","authenticated-orcid":false,"given":"Helena S","family":"Gouveia","sequence":"first","affiliation":[{"name":"Medical Oncology Department, Centro Hospitalar de Entre Douro e Vouga, EPE, Santa Maria da Feira, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00edlvia O","family":"Lopes","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Centro Hospitalar do Porto, Porto, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Lu\u00edsa","family":"Faria","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Centro Hospitalar de Entre Douro e Vouga, EPE, Santa Maria da Feira, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,3,15]]},"reference":[{"key":"2025082805215046000_2018.mar15_1.bcr-2017-223474.1","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.7.2.233"},{"key":"2025082805215046000_2018.mar15_1.bcr-2017-223474.2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.111251"},{"key":"2025082805215046000_2018.mar15_1.bcr-2017-223474.3","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13290"},{"key":"2025082805215046000_2018.mar15_1.bcr-2017-223474.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2006.09.005"},{"key":"2025082805215046000_2018.mar15_1.bcr-2017-223474.5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08143.x"},{"key":"2025082805215046000_2018.mar15_1.bcr-2017-223474.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(97)00153-8"},{"key":"2025082805215046000_2018.mar15_1.bcr-2017-223474.7","first-page":"249","article-title":"Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients","volume":"11","author":"Annemans","year":"2003","journal-title":"Support Care Cancer"},{"key":"2025082805215046000_2018.mar15_1.bcr-2017-223474.8","doi-asserted-by":"crossref","first-page":"204","DOI":"10.4143\/crt.2014.46.2.204","article-title":"Tumor lysis syndrome in a patient with metastatic colon cancer after treatment with 5-fluorouracil\/leucovorin and oxaliplatin: case report and literature review","volume":"46","author":"Kim","year":"2014","journal-title":"Cancer Res Treat"},{"key":"2025082805215046000_2018.mar15_1.bcr-2017-223474.9","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jcrpr.2016.03.001","article-title":"Tumor lysis syndrome in a patient with metastatic colon cancer after treatment with oxaliplatin and 5-Fu","volume":"3","author":"Tseng","year":"2016","journal-title":"J Cancer Res Pract"},{"key":"2025082805215046000_2018.mar15_1.bcr-2017-223474.10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.7603"},{"key":"2025082805215046000_2018.mar15_1.bcr-2017-223474.11","first-page":"714","article-title":"[Tumor lysis syndrome after FOLFIRI+cetuximab for ascending colon cancer]","volume":"112","author":"Matsuyama","year":"2015","journal-title":"Nihon Shokakibyo Gakkai Zasshi"},{"key":"2025082805215046000_2018.mar15_1.bcr-2017-223474.12","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/0959-8049(95)00654-0","article-title":"Rapid tumour lysis syndrome in a metastatic colorectal cancer increased by treatment with irinotecan (CPT-11)","volume":"32","author":"Boisseau","year":"1996","journal-title":"Eur J Cancer"},{"key":"2025082805215046000_2018.mar15_1.bcr-2017-223474.13","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1179\/joc.2000.12.3.244","article-title":"Colorectal cancer: dilemmas regarding patient selection and toxicity prediction","volume":"12","author":"Nikolic-Tomasevic","year":"2000","journal-title":"J Chemother"},{"key":"2025082805215046000_2018.mar15_1.bcr-2017-223474.14","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-200301000-00008"},{"key":"2025082805215046000_2018.mar15_1.bcr-2017-223474.15","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.revmed.2004.06.008","article-title":"[Tumor lysis syndrome after chemotherapy for colon small cell carcinoma]","volume":"25","author":"El Mesbahi","year":"2004","journal-title":"Rev Med Interne"},{"key":"2025082805215046000_2018.mar15_1.bcr-2017-223474.16","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1177\/030089160409000515","article-title":"Rapid tumor lysis syndrome in a patient with metastatic colon cancer as a complication of treatment with 5-fluorouracil\/leucoverin and irinotecan","volume":"90","author":"Oztop","year":"2004","journal-title":"Tumori"},{"key":"2025082805215046000_2018.mar15_1.bcr-2017-223474.17","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/02841860701460533","article-title":"Fatal tumor lysis syndrome after irinotecan\/5-FU\/folinic acid\/bevacizumab-containing therapy in a patient heavily pretreated for metastatic colon cancer","volume":"47","author":"Hentrich","year":"2008","journal-title":"Acta Oncol"},{"key":"2025082805215046000_2018.mar15_1.bcr-2017-223474.18","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.fjs.2013.09.002","article-title":"Fatal tumor lysis syndrome in a patient with metastatic colon cancer after palliative chemotherapy","volume":"46","author":"Hsieh","year":"2013","journal-title":"Formosan J Surg"},{"key":"2025082805215046000_2018.mar15_1.bcr-2017-223474.19","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2014-205002"},{"key":"2025082805215046000_2018.mar15_1.bcr-2017-223474.20","first-page":"e5","article-title":"An aggressive presentation of colorectal cancer with an atypical lymphoproliferative pattern of metastatic disease: a case report and review of the literature","volume":"13","author":"Shah","year":"2014","journal-title":"Clin Colorectal Cancer"},{"key":"2025082805215046000_2018.mar15_1.bcr-2017-223474.21","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s12029-015-9711-6","article-title":"Tumor lysis syndrome in metastatic colon cancer following treatment with regorafenib","volume":"46","author":"Farooqi","year":"2015","journal-title":"J Gastrointest Cancer"},{"key":"2025082805215046000_2018.mar15_1.bcr-2017-223474.22","doi-asserted-by":"crossref","unstructured":"Berringer R . Spontaneous tumor lysis syndrome in a patient with newly diagnosed metastatic colonic adenocarcinoma. CJEM 2017:1\u20133.doi:10.1017\/cem.2017.378","DOI":"10.1017\/cem.2017.378"},{"key":"2025082805215046000_2018.mar15_1.bcr-2017-223474.23","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/ccr3.1269","article-title":"Spontaneous tumor lysis syndrome in colon cancer: a case report and literature review","volume":"5","author":"Sommerhalder","year":"2017","journal-title":"Clin Case Rep"},{"key":"2025082805215046000_2018.mar15_1.bcr-2017-223474.24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/468452","article-title":"An unusual presentation of tumor lysis syndrome in a patient with advanced gastric adenocarcinoma: case report and literature review","volume":"2012","author":"Vodopivec","year":"2012","journal-title":"Case Rep Med"},{"issue":"3_suppl","key":"2025082805215046000_2018.mar15_1.bcr-2017-223474.25","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1200\/jco.2014.32.3_suppl.572","article-title":"Tumor burden (TB) as a prognostic indicator in patients with metastatic colorectal cancer (mCRC)","volume":"32","author":"Kwj","year":"2014","journal-title":"J Clin Oncol"},{"key":"2025082805215046000_2018.mar15_1.bcr-2017-223474.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0904569"},{"key":"2025082805215046000_2018.mar15_1.bcr-2017-223474.27","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13403"},{"key":"2025082805215046000_2018.mar15_1.bcr-2017-223474.28","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12665"},{"key":"2025082805215046000_2018.mar15_1.bcr-2017-223474.29","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/1756-185X.13143","article-title":"Diagnostic utility of HLA-B*5801 screening in severe allopurinol hypersensitivity syndrome: an updated systematic review and meta-analysis","volume":"20","author":"Yu","year":"2017","journal-title":"Int J Rheum Dis"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2017-223474","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:21:58Z","timestamp":1756383718000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2017-223474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,15]]},"references-count":29,"alternative-id":["10.1136\/bcr-2017-223474"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2017-223474","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,15]]}}}